Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neuphoria Therapeutics Inc (NEUP)

Neuphoria Therapeutics Inc (NEUP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,372
  • Shares Outstanding, K 5,391
  • Annual Sales, $ 15,650 K
  • Annual Income, $ -370 K
  • EBIT $ -4 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.52
  • Price/Sales 1.50
  • Price/Cash Flow 27.98
  • Price/Book 0.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.56
  • Number of Estimates 1
  • High Estimate -0.56
  • Low Estimate -0.56
  • Prior Year 6.55
  • Growth Rate Est. (year over year) -108.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.94 +5.33%
on 02/11/26
4.50 -7.78%
on 02/25/26
+0.10 (+2.47%)
since 01/27/26
3-Month
3.64 +13.85%
on 12/29/25
4.65 -10.75%
on 12/09/25
-0.21 (-4.82%)
since 11/26/25
52-Week
3.64 +13.85%
on 12/29/25
21.40 -80.61%
on 10/07/25
-1.04 (-20.04%)
since 02/27/25

Most Recent Stories

More News
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Company Urges Shareholders to Follow ISS’ Recommendation and Vote the  WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria”...

NEUP : 4.15 (-4.82%)
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy...

NEUP : 4.15 (-4.82%)
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing...

NEUP : 4.15 (-4.82%)
Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov....

NEUP : 4.15 (-4.82%)
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE...

NEUP : 4.15 (-4.82%)
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments...

NEUP : 4.15 (-4.82%)
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE)...

NEUP : 4.15 (-4.82%)
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal...

NEUP : 4.15 (-4.82%)
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments...

NEUP : 4.15 (-4.82%)
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments...

NEUP : 4.15 (-4.82%)

Business Summary

Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.

See More

Key Turning Points

3rd Resistance Point 4.62
2nd Resistance Point 4.51
1st Resistance Point 4.33
Last Price 4.15
1st Support Level 4.03
2nd Support Level 3.91
3rd Support Level 3.73

See More

52-Week High 21.40
Fibonacci 61.8% 14.62
Fibonacci 50% 12.52
Fibonacci 38.2% 10.43
Last Price 4.15
52-Week Low 3.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar